India Glycols' Scheme of Arrangement Sanctioned by NCLT
India Glycols Limited's Scheme of Arrangement has been sanctioned by the NCLT, transferring its Bio Pharma and Spirits & Biofuel undertakings to EBL and ISL, respectively. The Appointed Date is April 1, 2026. The NCLT order was dated July 17, 2026.
The scheme of arrangement involves the demerger of business undertakings, which is a significant corporate action that can impact the company's structure and future operations.
The NCLT sanctioning the scheme of arrangement is a positive development for the company's restructuring efforts.
India Glycols Limited has received the sanction for its Scheme of Arrangement from the Hon'ble National Company Law Tribunal (NCLT), Allahabad Bench at Prayagraj. The order, dated 17th July 2026 and uploaded on 20th July 2026, facilitates the transfer and vesting of the Bio Pharma and Spirits and Biofuel Undertakings into Ennature Bio Pharma Limited (EBL) and IGL Spirits Limited (ISL), respectively. The Appointed Date for the scheme is 1st April 2026.
The NCLT's order follows extensive procedural steps, including the approval of the scheme by India Glycols' equity shareholders and a majority of its unsecured creditors. Various statutory authorities, including the Registrar of Companies and the Regional Director, Ministry of Corporate Affairs, were consulted, and their representations were addressed. The Income Tax Department raised concerns regarding an outstanding demand of ₹27,890 against India Glycols Limited for AY 2024-25, which the company has clarified was paid on 6th July 2023 and has requested rectification on the Income Tax Portal. The company has provided undertakings to address the Income Tax Department's concerns and ensure compliance with all applicable laws.
The scheme ensures that the terms and conditions of employment for employees of the demerged undertakings are preserved. India Glycols Limited will inform the stock exchanges separately about the Effective Date of the Scheme.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under amalgamation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.